VERO Venus Concept

Venus Concept Launches “NEXThetics” Program

Venus Concept Launches “NEXThetics” Program

New Venus AI Event Series Focused on Enhancing Customer Education and Training

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic technology leader, announces the launch of “NEXThetics”, its new series of customer education and training events. NEXThetics is the newest advancement under the Company’s recent “Venus Aesthetic Intelligence” (or “Venus AI”) rebrand. NEXThetics events also provide professionals from all sectors of the aesthetics industry a networking opportunity to come together and exchange ideas, share success stories, and forge valuable connections.

“As we continue to evolve under the Venus AI banner, we are enhancing our focus on physician education and practice enhancement programs by empowering professionals in the aesthetics field with the knowledge, tools, and support they need for them to thrive. Aesthetic intelligence is not just about our emerging technologies such as robotics or artificial intelligence but about how we shift our focus from device performance to total practice performance,” said Ross Portaro, Executive Vice President, and General Manager, Global Sales and Marketing. “This transition requires focusing on how we educate and train attendees on all aspects of running a successful practice, leveraging our technologies and services to grow their businesses.”

During NEXThetics events, attendees can experience live demonstrations led by top physicians, showcasing the effectiveness and versatility of Venus devices and services. Over the last four months, the Company hosted several pilot events in Dallas, Miami, Toronto, and Atlanta, which have been well received by customers and industry professionals. In these events, leading industry luminaries including Dr. Scott Gerrish, Dr. Gilly Munavalli and others shared their hands-on experience with the audience, presented success stories, and discussed other elements that are essential in building a successful practice, such as marketing programs, customer service, and post treatment care.

“In 2024, we are looking to continue building on the success of our pilot NEXThetics events and drive innovation and education within aesthetics and hair restoration. Our NEXThetics program is another platform we offer to our customers that will elevate their practice and help them stay ahead of the curve,” explained Hemanth Varghese, President & Chief Operating Officer of Venus Concept.

The next upcoming NEXThetic events will be held in early-June in Cleveland, Ohio and New York City, New York.

About Venus Concept

Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 12 direct markets. Venus Concept’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa Pro, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept’s hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.



Investor Relations Contact:
ICR Westwicke on behalf of Venus Concept: 
Mike Piccinino, CFA
 
EN
12/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Venus Concept

 PRESS RELEASE

Venus Concept Announces Intention to Voluntary Delist from Nasdaq and ...

Venus Concept Announces Intention to Voluntary Delist from Nasdaq and Deregister with SEC TORONTO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) announced today its voluntarily decision to delist its common stock from the NASDAQ Capital Market (“Nasdaq”) and deregister its common stock with the Securities and Exchange Commission (the “SEC”). The Company is in compliance with applicable Nasdaq listing requirements, but the Company’s Board of Directors has concluded the resources required to continue its reporting obligations with the SEC are great...

 PRESS RELEASE

Venus Concept Announces Third Quarter 2025 Financial Results

Venus Concept Announces Third Quarter 2025 Financial Results TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2025. Summary of Financial Results & Recent Progress: Energy Based Device (“EBD”) revenues showing signs of stabilization. Total EBD systems sales of $9.6 million, up 2% year over year Total revenue for the third quarter of $13.8 million, down 8% year-over-year and down 12% qua...

 PRESS RELEASE

Venus Concept Receives 510(k) for the Venus NOVA, Its Most Advanced Mu...

Venus Concept Receives 510(k) for the Venus NOVA, Its Most Advanced Multi-Application Platform for Non-Invasive Body and Skin Treatments Venus NOVA is the first product clearance from the Company’s new R&D strategy TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global leader in medical aesthetic technology, announced today that it has received a 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market the Venus NOVA™, the Company’s next-generation multi-application platform designed to redefine non-invasive treatm...

 PRESS RELEASE

Venus Concept Announces $11.48 Million Debt-to-Equity Exchange Transac...

Venus Concept Announces $11.48 Million Debt-to-Equity Exchange Transaction Reduction of outstanding debt by Madryn Asset Management continues to improve the Company’s financial position TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that, on September 30, 2025, the Company exchanged the full $11.48 million balance of its subordinated convertible notes held by affiliates of Madryn Asset Management, LP (“Madryn”) for 545,335 shares of its Series Y preferred stock...

 PRESS RELEASE

Venus Concept to Release Third Quarter of Fiscal Year 2025 Financial R...

Venus Concept to Release Third Quarter of Fiscal Year 2025 Financial Results on November 13, 2025 TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, November 13, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on November 13, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to par...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch